PharmacyCodes



Apo-Timop en es it fr

Apo-Timop Brand names, Apo-Timop Analogs

Apo-Timop Brand Names Mixture

  • Combigan (Brimonidine Tartrate + Timolol Maleate)
  • Cosopt -(2%/0.5% Oph Dps) (Dorzolamide Hydrochloride + Timolol Maleate)
  • Timolide Tab (Hydrochlorothiazide + Timolol Maleate)
  • Timpilo 2 (Pilocarpine Hydrochloride + Timolol Maleate)
  • Timpilo 4 (Pilocarpine Hydrochloride + Timolol Maleate)
  • Xalacom (Latanoprost + Timolol Maleate)

Apo-Timop Chemical_Formula

C13H24N4O3S

Apo-Timop RX_link

http://www.rxlist.com/cgi/generic3/timololgfs.htm

Apo-Timop fda sheet

Apo-Timop FDA

Apo-Timop msds (material safety sheet)

Apo-Timop MSDS

Apo-Timop Synthesis Reference

Wasson et al., J. Med. Chem. 15, 615 (1972)

Apo-Timop Molecular Weight

316.421 g/mol

Apo-Timop Melting Point

201.5-202.5 oC

Apo-Timop H2O Solubility

2.74 mg/mL

Apo-Timop State

Solid

Apo-Timop LogP

1.761

Apo-Timop Dosage Forms

Drops; Liquid; Solution; Solution (long-acting); Tablet

Apo-Timop Indication

In its oral form it is used to treat high blood pressure and prevent heart attacks, and occasionally to prevent migraine headaches. In its opthalmic form it is used to treat open-angle and occasionally secondary glaucoma.

Apo-Timop Pharmacology

Similar to propranolol and nadolol, timolol is a non-selective, beta-adrenergic receptor antagonist. Timolol does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity, but does possess a relatively high degree of lipid solubility. Timolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage.

Apo-Timop Absorption

Bioavailability is about 60%

Apo-Timop side effects and Toxicity

LD50=1190 mg/kg (oral, mice), LD50=900 mg/kg (oral, rat). Symptoms of overdose include drowsiness, vertigo, headache, and atriventricular block.

Apo-Timop Patient Information

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Patients should also be instructed that ocular solutions, if handled improperly, could become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g.,trauma or infection), they should immediately seek their physicianís advice concerning the continued use of the present multidose container. Patients should be instructed to invert the closed container and shake once before each use. It is not necessary to shake the container more than once. Patients requiring concomitant topical ophthalmic medications should be instructed to administer these at least 10 minutes before instilling Timolol GFS. Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. Transient blurred vision or visual disturbance, generally lasting from 30 seconds to 5 minutes, following instillation may impair the ability to perform hazardous tasks such as operating machinery or driving a motor vehicle.

Apo-Timop Organisms Affected

Humans and other mammals